, an oral selective inhibitor of human epidermal growth factor receptors 1 (or epidermal growth factor receptor), 2, and 4, and vascular endothelial growth factor receptors 1, 2, and 3, is being developed as a treatment for patients with non-small-cell lung cancer and metastatic breast cancer. The disposition of [ 14 C]BMS-690514 was investigated in nine healthy male subjects (group 1, n ‫؍‬ 6; group 2, n ‫؍‬ 3) after oral administration of a 200-mg dose. Urine, feces, and plasma were collected from all subjects for up to 12 days postdose. In group 2 subjects, bile was collected from 3 to 8 h postdose. Across groups, approximately 50 and 34% of administered radioactivity was recovered in the feces and urine, respectively. An additional 16% was recovered in the bile of group 2 subjects. Less than 28% of the dose was recovered as parent drug in the combined excreta, suggesting that BMS-690514 was highly metabolized. BMS-690514 was rapidly absorbed (median time of maximum observed concentration 0.5 h) with the absorbed fraction estimated to be approximately 50 to 68%. BMS-690514 represented <7.9% of the area under the concentration-time curve from time 0 extrapolated to infinite time of plasma radioactivity, indicating that the majority of the circulating radioactivity was from metabolites. BMS-690514 was metabolized via multiple oxidation reactions and direct glucuronidation. Circulating metabolites included a hydroxylated rearrangement product (M1), a direct ether glucuronide (M6), and multiple secondary glucuronide conjugates. None of these metabolites is expected to contribute to the pharmacology of BMS-690514. In summary, BMS-690514 was well absorbed and extensively metabolized via multiple metabolic pathways in humans, with excretion of drug-related radioactivity in both bile and urine.
Introduction
(3R,4R)-4-Amino-1- ((4-((3-methoxyphenyl) amino)pyrrolo [2,1-f] [1, 2, 4] triazin-5-yl)methyl)-3-piperidinol (BMS-690514) is a new highly selective and potent orally administered small molecule inhibitor of human epidermal growth factor receptors, HER1 (EGFR), HER2, and 4, and vascular endothelial growth factor receptors, VEGFR1, 2 and 3, all key pathways in cancer pathogenesis and progression (Herbst et al., 2005; Tortora et al., 2008) . Preclinical studies have shown that BMS-690514 exerts its antiproliferative and proapoptotic effects in a variety of non-small-cell lung cancer (NSCLC) cell lines (de La Motte Rouge et al., 2007) and xenograft models dependent on EGFR and HER2 signaling (Wong et al., 2007) . Although multiple agents, including monoclonal antibodies and tyrosine kinase inhibitors, have shown efficacy in treating advanced NSCLC and other solid tumors by inhibition of individual VEGF or EGFR pathways (Fukuoka et al., 2003; Kris et al., 2003; Shepherd et al., 2005; Sandler et al., 2006; Reck et al., 2009) , recent literature reports have suggested the potential for enhanced antitumor activity through the simultaneous inhibition of both pathways (Tabernero, 2007; Tortora et al., 2008) . BMS-690514 is currently under development as an oral agent for the treatment of patients with NSCLC, metastatic breast cancer, and other solid tumor malignancies. BMS-690514 showed evidence of antitumor activity and disease control in a phase I/II study of 62 patients with advanced NSCLC, including those with erlotinib resistance and those with wild-type EGFR, Exon 19-and 21-activating EGFR mutations, EGFR T790M, or K-ras mutations (Bahleda et al., 2008 (Bahleda et al., , 2009 ). BMS-690514 was generally well tolerated with manageable side effects.
The pharmacokinetics of BMS-690514 was evaluated in mouse, rat, dog, and monkey. The results from these studies indicated that the bioavailability of the drug was high in mice and rats (77 and 100%, respectively), moderate in dogs (29%), and low in monkeys (8%) (Marathe et al., 2010) . Disposition studies with [ 14 C]BMS-690514 in rats and dogs demonstrated that the compound was primarily cleared by metabolism, with the majority of drug-related radioactivity excreted in the bile or feces (Hong et al., 2010) . The primary pathways for metabolism of BMS-690514 in the animal species were hydroxylation, O-demethylation, and direct glucuronidation (Marathe et al., 2010) . These were also the pathways observed in incubations of [ 3 H]BMS-690514 with human hepatocytes, with direct glucuronidation being the most prominent pathway. In vitro studies with expressed enzymes suggested that CYP2D6 and CYP3A4 enzymes are likely to play an important role in the oxidative metabolism of BMS-690514 (Marathe et al., 2010) .
The objectives of the present study were to characterize the absorption, metabolism, and excretion of [ 14 C]BMS-690514, as well as the pharmacokinetics of BMS-690514 and drug-derived 14 C in healthy male subjects after a single 200-mg p.o. dose. The selection of a 200-mg dose was based on the maximum tolerated dose identified in a previous clinical study in patients with cancer (Bahleda et al., 2008) . Because biliary excretion was an important pathway for elimination of drug-related radioactivity in rats and dogs and glucuronidation was a major metabolic pathway observed in incubations with human hepatocytes, bile was collected from three subjects to evaluate the role of direct glucuronidation in the overall metabolism of the compound in humans. Furthermore, to capture the complete pharmacokinetics of drug-derived 14 C, accelerator mass spectrometry (AMS) was used. The selection of AMS rather than traditional liquid scintillation counting (LSC) was based on a prospective evaluation, which suggested that at a dose of 200 mg and a specific activity of 0.39 Ci/mg, the LSC protocol used in our laboratory (Christopher et al., 2008) would not provide sufficient sensitivity to adequately characterize the elimination phase of the PK profile of radioactivity. In our experience, traditional LSC has not consistently provided adequate sensitivity to fully characterize the PK profile of radioactivity at later time points, particularly in instances in which compounds with low specific activity were administered (Christopher et al., 2008; Zhou et al., 2010) . Accelerator mass spectrometry, an ultrasensitive detection technique that relies on measurement of the 14 C/ 12 C ratio, rather than on decay counting (Lappin and Garner, 2004) , can help to bridge that gap. Over the past decade, the utility of AMS has been demonstrated in several pharmacokinetic and mass balance studies (Garner et al., 2002; Beumer et al., 2007; Boddy et al., 2007) .
Materials and Methods

Chemicals. [
14 C]BMS-690514 (0.39 Ci/mg, free base purity 99.2%, radiochemical purity 99.1%), uniformly labeled on the six aromatic carbons of the methoxyaniline group, was synthesized by Bristol-Myers Squibb Research and Development (Princeton, NJ). Analytical reference standards for HPLC, namely unlabeled BMS-690514, M2 (phenyl hydroxylated metabolite of BMS-690514, purity Ͼ99%), M3 (O-demethylated metabolite of BMS-690514, purity Ͼ99%), M6 (ether glucuronide conjugate of BMS-690514, purity 96%), and [ This was an open-label, nonrandomized, single-dose study. Nine healthy male subjects, all Caucasian, with a mean age of 37.0 years (range 18 -44 years) and a mean body mass index of 25.5 kg/m 2 (range 20.3-29.6 kg/m 2 ) participated in the study. The study was conducted in accordance with the Declaration of Helsinki and guidelines on Good Clinical Practice. Before study initiation, the study protocol and informed consent document were approved by the Institutional Review Board/Independent Ethics Committee, Ethik Kommission Beider (Basel, Switzerland). All study participants provided written informed consent before the initiation of any study-specific procedures, including the targeted pharmacogenetic analysis. Once enrolled, the subjects were assigned to one of two groups (group 1, subjects 1-6; group 2, subjects 7-9) by the study investigator. All subjects in both groups received a single 200-mg p.o. dose of [ 14 C]BMS-690514 containing 80 Ci of radioactivity (0.39 Ci/mg) in a solution of 50 mM citric acid.
Blood, urine, bile (group 2 only), and fecal samples were collected for pharmacokinetic and metabolite profiling analyses according to the sampling schedule in Table 1 . Blood samples, 6 ml each, were collected for measurement of plasma concentrations of total radioactivity (TRA) and BMS-690514. The samples were collected into Becton-Dickinson Vacutainer tubes (BD, Franklin Lakes, NJ), containing EDTA as an anticoagulant. After mixing, the samples were centrifuged for 15 min at approximately 1000g at 5°C to separate plasma. A 1-ml aliquot of each plasma sample was transferred to a separate tube for measurement of plasma TRA (i.e., drug-derived 14 C by AMS). The remaining plasma was used for assessment of BMS-690514 concentrations. All samples were stored at Ϫ20°C until analysis. Additional blood samples (10 ml each) were collected for biotransformation analysis. Plasma samples were prepared as above and stored at Ϫ70°C or below until analysis.
The entire urinary and fecal output for each subject was collected for at least 9 days after dosing or until study discharge. After the required 9-day period, subjects could be discharged from the study provided that at least 80% of the total dose of radioactivity was collected or the measurement of radioactivity excreted in the urine and feces combined for the most recent 24-h collection period was Ͻ1% of the administered radioactivity. If these criteria were not achieved, subjects remained in the study, and samples were collected for subsequent days until the discharge criteria were met, up to a maximum of 12 days. Immediately after collection, urine samples were acidified with glacial acetic acid, final concentration 1% (v/v). The bulk urine samples were stored under refrigerated conditions until the end of the collection interval. At the end of each interval, the bulk urine samples were mixed well, and a 10-ml aliquot of each urine sample was transferred to a vial for analysis of TRA by LSC. A 4-ml aliquot was transferred to a separate vial for analysis of urine BMS-690514 concentrations. These samples were stored at Ϫ20°C until analysis. The remainder of the bulk urine for each collection interval was used to prepare individual and pooled samples for biotransformation analysis. Samples for biotransformation analysis were stored at Ϫ70°C or below.
Fecal samples were transferred to tared containers and homogenized with approximately 2 to 3 volumes of water. The weight of fecal homog-enate was recorded for each sample. For each collection interval, ϳ10 g of each fecal homogenate sample was transferred to a separate container for measurement of TRA by LSC. The remaining bulk fecal homogenate samples were used for preparing pooled samples for biotransformation analyses. The fecal homogenate samples were stored at Ϫ20°C or below until analysis.
Bile samples were collected from group 2 subjects from 3 to 8 h postdose. For these subjects, 1 h after drug administration, the terminal end of an oral gastroduodenal tube was positioned at the vertical limb of the duodenal loop, near the ampulla of Vater (confirmed via fluoroscopy). Metoclopramide (10 mg) was administered intravenously at approximately 1 h after the BMS-690514 dose to facilitate insertion of the collection tube. Three fractions were Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 , and 216 h postdose Time points for collection of blood samples for metabolite profiling of plasma Predose and 1, 2, 4, 8, 12, 24, 48, 96 , and 168 h postdose Urine collection intervals [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org collected over the intervals of 3 to 4, 4 to 6, and 6 to 8 h. At 7 h postdose, an intravenous dose of sincalide (20 ng/kg over 5 min) was given to stimulate gallbladder contraction and enhance bile flow. For each collection interval, a 1-ml aliquot of bile was transferred to a separate vial for assessment of TRA by LSC, and the remainder was used for biotransformation analysis. The bile samples were immediately frozen and stored at Ϫ70°C or below. Measurement of Radioactivity. Plasma. The concentration of drug-derived 14 C radioactivity in individual plasma samples was determined by AMS at Accium Biosciences (Seattle, WA). A detailed procedure describing the use of AMS for this purpose has been described previously (Garner et al., 2000) . Portions of each of the plasma pharmacokinetic samples were converted to graphite in a two-step process involving oxidation to carbon dioxide followed by reduction (Vogel, 1992) . Predose samples were processed without dilution, whereas postdose samples were diluted and tributyrin (carrier carbon) was added before the graphitization procedure. The resulting graphite samples were pressed into cathodes and the 14 C/ 12 C isotope ratio was determined using a 1.5SDH Compact AMS system (National Electrostatics Corporation, Middleton, WI).
The total carbon content of plasma from each subject was determined with a Shimadzu V-Series Total Organic Carbon Analyzer (Shimadzu, Torrance, CA). Portions (ϳ0.1 ml) of selected plasma samples from each subject (predose and 2, 24, 96, and 168 h postdose) were diluted approximately 370-fold with HPLCgrade water before analysis. The average total plasma carbon content for each subject (which ranged from 37.3 to 45.1 mg of carbon/ml) and the 14 C/ 12 C isotope ratio obtained for each individual sample were used to calculate the total 14 C radioactivity in plasma (disintegrations per minute per milliliter).
For each subject, the natural Excreta. The levels of TRA in individual urine, bile, and feces samples were determined by LSC. Aliquots of urine (1 ml) and bile (0.05 ml) were counted in duplicate by mixing with 10 ml of Irga-Safe Plus scintillation cocktail. Aliquots of fecal homogenate (ϳ150 -200 mg), in quadruplicate, were digested for at least 16 h at 40°C with 2 ml of Solvable. After cooling, 18 ml of Irga-Safe Plus was added to each solubilized fecal sample. For urine and fecal samples, quality control samples were prepared by spiking a known amount of [ 14 C]stearic acid stock solution into blank urine or feces. After the addition of scintillation cocktail, all samples were vortex mixed and analyzed for 10 min on a Packard 2900 TR liquid scintillation counter. All radioactivity measurements were corrected with a background of 19 cpm (historical background). Compound equivalents were determined by dividing the microcuries per gram or per milliliter of sample by the specific activity (0.39 Ci/mg). Radioactivity in the urine, feces, and bile was expressed as a percentage of the administered dose. The LOQs for each matrix were calculated according to the method of Currie (1968) and were 20 dpm/ml (24 ng-Eq/ml) for urine, 23 dpm/ml (263 ng-Eq/ml) for bile, and 23 dpm/ml (176 ng-Eq/g of homogenate) for feces.
Quantification of BMS-690514 Concentrations in Plasma and Urine. The concentrations of BMS-690514 in individual plasma and urine samples were determined with validated liquid chromatography/tandem mass spectrometry (LC-MS/MS) methods. In brief, after addition of stable labeled internal standard ([ 13 C 6 ]BMS-690514) to each plasma or urine sample, the analytes were isolated by solid-phase extraction. The eluates from the solidphase extraction were then applied to a reverse-phase HPLC column. The HPLC system consisted of an LCPAL autosampler (CTC Analytics, Zwingen, Switzerland) and an HP 1100 series pump (Agilent Technologies, Santa Clara, CA). The HPLC system was interfaced to a Sciex API4000 mass spectrometer (Applied Biosystems, Foster City, CA) that was operated in the positive ion electrospray mode. BMS-690514 and its internal standard were monitored by multiple reaction monitoring with transitions that were specific for each analyte. The standard curve ranges were 0.5 to 100 ng/ml for plasma and 1 to 100 ng/ml for urine.
Pharmacokinetic Analysis of BMS-690514 and TRA. The pharmacokinetic parameters of BMS-690514 and radioactivity were determined from plasma concentration versus time profiles and urinary excretion data using a noncompartmental method with Kinetica 4.4.1 in eToolbox (Thermo Fisher Scientific, Waltham, MA).
The single-dose pharmacokinetic parameters assessed included maximum observed concentration (C max C max and T max were obtained from experimental observations. The terminal log-linear phase of the concentration-time curve was identified by leastsquares linear regression of at least three data points that yielded a maximum G-criterion, which is also referred to as adjusted R-squared, using no weighting factor. The T-HALF was calculated as ln2/K el , where K el was the absolute value of the slope of the terminal log-linear phase. The AUC(0 -T) was calculated by the mixed log-linear trapezoidal algorithm in Kinetica. The AUC(INF) was estimated by summing AUC(0 -T) and the extrapolated area, computed by the quotient of the last observable concentration and K el . The amount of BMS-690514 and TRA excreted in urine and TRA in bile and feces during each collection interval was calculated by multiplying the concentration of each analyte by the volume or weight of matrix collected over that interval. The total urinary recovery, biliary recovery, or fecal recovery was calculated as the cumulative amount excreted over all the collection periods and expressed as a percentage of the administered [
14 C]BMS-690514 dose (%Urine, %Bile, or %Feces).
Estimation of Plasma Exposures of Metabolites. Plasma exposures, AUC(0 -8 h), of selected metabolites were estimated from the metabolite profiling data of 1, 2, 4, and 8 h plasma samples. The concentration of TRA in plasma samples (nanogram-equivalents per milliliter) was determined from the mean radioactivity of all subjects in each group at a given time point and the administered specific activity. The concentrations of parent compound and the metabolites were determined by multiplying the percent contribution of each compound in the pooled radioprofile by the TRA concentration at each time point. The AUC(0 -8 h) values for parent compound and metabolites were then calculated in Microsoft Excel 2003 (Microsoft, Redmond, WA) with the trapezoidal method.
Preparation of Samples for Biotransformation Profiling and Identification of Metabolites. For each group of subjects, representative pooled plasma, bile, urine, and fecal homogenate samples were prepared for metabolite profiling and identification experiments. Plasma samples were segregated by collection time (1, 2, 4, and 8 h), and equal volumes from all subjects within a treatment group were combined. Plasma biotransformation samples collected after 8 h were not analyzed because the radioactivity in these samples was too low to produce meaningful profiles. Bile was pooled across all group 2 subjects over the entire collection interval (3-8 h) by combining volumes proportional to the total volume collected from each subject for each collection interval. Urine (0 -192 h) was pooled across all subjects within a treatment group by combining volumes proportional to the total volume excreted from each subject for each collection interval. Likewise, fecal homogenate samples (0 -192 h) were pooled across all subjects within a treatment group by combining homogenate weights that were proportional to the homogenate weight for each subject for each collection interval. After pooling, samples for metabolite profiling were stored at Ϫ70°C or below before analysis.
Metabolite Profiling and Identification. Metabolic profiling and analysis of metabolites in human samples were performed on a Surveyor HPLC system with a photodiode array detector and LCQ Deca XP Plus mass spectrometer (Thermo Fisher Scientific). The method was used previously for the analysis of samples from preclinical studies and has been described in detail (Hong et al., 2010) . Chromatography was performed on a YMC ODS-AQ HPLC column (4.6 ϫ 150 mm, 120 Å, 5 m) maintained at ambient temperature (Waters, Milford, MA). The flow rate was 1 ml/min. Separation of the sample components was achieved over a 60-min run time with a stepped gradient containing two mobile phases: 10 mM ammonium acetate in water with 2052 CHRISTOPHER ET AL.
at ASPET Journals on November 6, 2017 dmd.aspetjournals.org acetonitrile (95:5 v/v, mobile phase A) and 100% acetonitrile (mobile phase B). An accurate postcolumn splitter (LC Packings, San Francisco, CA) was installed after the photodiode array detector, diverting 75% of the column eluate to a fraction collector (Gilson, Inc., Middleton, WI), for generation of metabolite profiles and the remaining 25% of the eluate into the mass spectrometer for identification of metabolites.
The flow from the fraction collector was collected in 96-well Luma plates (PerkinElmer Life and Analytical Sciences) at a collection rate of 0.25 min/ well. The plates were evaporated to dryness on a Savant Speed-Vac (Thermo Fisher Scientific) and assayed for radioactivity (10 min/well) with a TopCount Microplate Scintillation Counter (PerkinElmer Life Sciences). Radiochromatographic metabolite profiles were prepared by plotting the net counts per minute obtained from the TopCount versus time after injection with Microsoft Excel. The relative abundance of metabolites in each sample was determined on the basis of the total percentage of radioactivity for each metabolite peak relative to the total radioactivity in the entire chromatogram.
The metabolites were identified with the LCQ Deca XP Plus mass spectrometer, which was equipped with an electrospray ionization source and was operated in positive ion mode. The capillary temperature was 350°C, and the spray voltage was 5 kV. The nitrogen gas flow rate, capillary voltage, and tube lens voltage were periodically adjusted to give maximum sensitivity or fragmentation of drug-related components. Product ions were generated via collision-induced dissociation with helium at a normalized collision energy of 30% and a precursor ion isolation width of m/z 2.0. The structures of metabolites were proposed on the basis of their mass spectral fragmentation patterns relative to the parent compound or synthetic metabolite standards.
Pharmacogenetic Analysis. Because CYP2D6 was expected to play a role in the oxidative metabolism of BMS-690514 and the compound was also a substrate for direct glucuronidation in vitro (Marathe et al., 2010) , metabolic variability was studied by genotyping selected polymorphisms in CYP2D6 (*2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *15, *41, and 2XN alleles) and UGT1A1 (*28 allele). For single nucleotide polymorphism analysis, blood samples were obtained on day 1, before drug administration. DNA was extracted with the Gentra Puregene DNA Isolation Kit according to the manufacturer's instructions. After amplification by polymerase chain reaction, individual allele status was determined by gel electrophoresis of amplification products and restriction fragment length polymorphism analysis. Subjects having one or more copies of the UGT1A1*28 allele (TA7) were classified as exhibiting reduced expression; subjects homozygous for the UGT1A1*1 allele (TA6) were classified as exhibiting normal expression. CYP2D6 genotypes for individual subjects were assigned on the basis of the results of a panel of polymorphism-specific assays and in accordance with allele definitions as set forth by the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (http://www.cypalleles. ki.se/, 2009). CYP2D6 genotypes were then assigned predicted phenotypes based on the classification scheme of Chou et al. (2003) .
Isolation of Metabolite M1 for Pharmacological Activity Testing. BMS-690514 (50 M) was incubated with pooled human liver microsomes (1 mg/ml), fortified with 1 mM NADPH, in 100 mM phosphate buffer (pH 7.4) to promote the formation of M1. The incubation was conducted at 37°C in a shaking water bath for 1.5 h. At the end of the incubation period, an equal volume of ice-cold acetonitrile was added to the mixture to quench the reaction. After vortex mixing, the sample was centrifuged to precipitate proteins. The resulting supernatant was transferred to a new vial, frozen at Ϫ80°C, and then concentrated approximately 10-fold by lyophilization (AdVantage 2.0 Benchtop Freeze Dryer; VirTis, Gardiner, NY). Isolation of M1 from the concentrated sample was achieved on a Shimadzu LC-8A preparative HPLC system with a Synergi Fusion-RP column (150 ϫ 21.2 mm, 4 m in particle size and 80Å in pore size; Phenomenex, Torrance, CA). Drug-related components in the column eluate were monitored with a Shimadzu photodiode array detector, set at a wavelength of 264 nm. The HPLC mobile phase consisted of two solvents: mobile phase A (10 mM ammonium acetate in water and acetonitrile, 95:5, v/v, pH 5.0) and mobile phase B (100% acetonitrile). The gradient program used for separation was as follows: hold isocratic at 0% B (0 -5 min); linear gradient from 0 to 35% B (5-40 min); linear gradient from 35 to 90% B (40 -45 min); hold isocratic at 90% B (45-50 min); and reequilibrate at 0% B for 10 min. The mobile phase flow rate was 10 ml/min. The HPLC fractions containing M1 were collected on ice and dried by lyophilization. With this procedure, approximately 250 g of M1, with an estimated purity of 96% was isolated for evaluation in in vitro protein kinase inhibition assays.
Protein Kinase Inhibition Assays. In vitro kinase assays were conducted to evaluate the inhibitory activities of BMS-690514 and selected metabolites (M1, M2, M3, and M6) toward HER1, HER2, and VEGFR2. All kinase assays were performed in 96-well plates as described previously (Wong et al., 2006) . Recombinant HER1 and HER2 were expressed as described previously (Wong et al., 2006) . The cytoplasmic sequences of VEGFR2 were expressed as a fusion protein with glutathione transferase in insect cells and were purified by affinity chromatography on glutathione Sepharose columns (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The percent inhibition of kinase activity in the presence of test compounds was reported as the inhibitory concentration required to achieve 50% inhibition relative to control reactions without an inhibitor (IC 50 ).
Cell Culture and Proliferation Assay. BMS-690514 and selected metabolites (M2, M3, and M6) were evaluated for their ability to inhibit cell proliferation of N87 gastric carcinoma cells, a cell line with HER2 gene amplification, as described previously (Wong et al., 2006) .
Results
Recovery of the Radioactive Dose in Urine, Feces, and Bile. After oral administration of [ 14 C]BMS-690514 to healthy male subjects, the mean cumulative recovery of radioactivity over the study duration (264 h) was 90.28% (85.42% for group 1 and 99.98% for group 2) (Fig. 2) . For both groups, the majority of radioactivity, 50 to 52%, was recovered in the feces and approximately 34% was recovered in the urine. For group 2 subjects an additional 16% of the dose was recovered in the bile over the 3 to 8 h postdose interval. For group 1 subjects, the cumulative excretion of [ 14 C]BMS-690514-derived radioactivity was 68% by 72 h postdose (Fig. 2) ; the excretion rate reached a plateau at 144 h postdose (mean 82% total recovery) with Ͻ2% daily incremental changes thereafter. For the group 2 subjects, the cumulative excretion of [
C]BMS-690514-derived radioactivity was approximately 77% by 72 h and reached a plateau at 96 h postdose.
Pharmacokinetics of Total Radioactivity and BMS-690514 in Healthy Male Subjects. The mean plasma concentration-time profiles and pharmacokinetic parameters for total radioactivity and BMS-690514 are shown in Fig. 3 and Table 2 , respectively. BMS-690514 was rapidly absorbed with T max values ranging from 0.5 to 2 h postdose. T max values for TRA occurred between 1.5 and 4.0 h postdose and reflect a composite plasma concentration-time profile of BMS-690514 and its metabolites in plasma. Based on AUC(INF) values, BMS-690514 accounted for approximately 3.4 and 7.9% of the circulating radioactivity in group 1 and group 2 subjects, respectively, suggesting that metabolites contributed significantly to the circulating radioactivity. Plasma TRA was eliminated from the systemic circulation at a slower rate (T-HALF Ͼ170 h) than was the parent drug, which had a mean T-HALF of 16 to 18 h. Subjects who went through bile collection had generally lower systemic exposures to TRA than those who did not have bile collection, although both groups had similar exposures to the parent drug. On the basis of measurements of BMS-690514 with a validated LC-MS/MS assay, Ͻ3.5% of the administered dose was excreted in urine as unchanged parent drug.
Identification of Metabolites. Metabolites of BMS-690514 in plasma, urine, bile, and feces samples were characterized by LC-MS/MS analysis. Confirmation of the identity of parent compound, M2, M3, and M6 was further supported by comparison of HPLC retention times and mass spectral fragmentation patterns with those of synthetic reference standards. A detailed description of the structural assignments for metabolites of BMS-690514 has been reported (Hong et al., 2010) . The proposed pathways for BMS-690514 metabolism and structures of metabolites identified in the human subjects in this study are shown in Fig. 1 .
Metabolite Profiles in Plasma, Urine, Feces, and Bile. The relative distribution of metabolites in pooled plasma samples from group 1 and group 2 subjects are summarized in Table 3 , and representative biotransformation profiles from the two groups at 1 and 4 h postdose are shown in Fig. 4 , A to D. After extraction, the recovery of radioactivity from plasma samples ranged from 75 to 97%. The two groups showed similar metabolic profiles, although the pooled sample from group 2 subjects had a higher proportion of M6, a direct glucuronide conjugate, at later time points. BMS-690514, two primary metabolites, M6 and M1 (a hydroxylated rearrangement product), and several glucuronide conjugates of oxidative metabolites, including M7 and M9, were prominent drug-related peaks in the plasma. The parent compound represented 33 to 41% of the plasma radioactivity at the 1-h time point, and this level decreased to approximately 16% of the plasma radioactivity by 8 h; metabolites, particularly the glucuronide ]BMS-690514 to healthy male subjects in groups 1 and 2. A, time course for excretion of radioactivity in urine, feces, and total excreta for group 1 subjects. B, time course for excretion of radioactivity in urine, feces, bile, and total excreta for group 2 subjects. C, cumulative recovery of the administered radioactive dose for groups 1 and 2.
conjugates, accounted for a greater proportion of radioactivity at later time points. The AUC(0 -8 h) exposures for BMS-690514, M1, M6, M7/M9 combined, and TRA were 915, 840, 1806, 767, and 5432 ng-Eq/h ⅐ ml, respectively, for group 1 subjects.
The relative distribution of metabolites in pooled excreta samples is summarized in Table 4 , and representative biotransformation profiles are shown in Fig. 5 , A to C. The average extraction recovery of radioactivity from feces samples was Ͼ100%. Consistent with the results from the validated bioanalytical assay for BMS-690514 in urine, which indicated that 3.0 to 4.2% of the parent drug was excreted in urine (Table 2) , the metabolite profiling experiments also suggested that parent drug accounted for a small portion of the dose excreted in urine (3.6 -7.0%). BMS-690514 represented only 0.6% of the dose excreted in bile but accounted for 17 to 20% of the dose in feces. In the combined excreta samples (urine and feces for group 1; urine, bile, and feces for group 2), BMS-690514 represented Ͻ28% of the administered dose, indicating that BMS-690514 was highly metabolized. The direct glucuronide conjugate, M6, was the predominant peak in the metabolite profiles of both urine and bile, whereas primary oxidative metabolites M1, M2, M3, and M37 were minor components. Multiple secondary glucuronide conjugates and M21, a secondary sulfate conjugate, were also observed in both matrices. In contrast, the parent compound, M2/M37, and M3 were the prominent peaks in the fecal profiles, and no conjugated metabolites were observed.
Pharmacogenetic Analyses. Based on genotyping analysis of UGT1A1, three subjects, subjects 1, 3, and 8, were homozygous for the *1 allele and were categorized as having normal expression of UGT1A1. The remaining six subjects had one or more *28 alleles and were characterized as having reduced UGT1A1 expression. The plasma AUC(INF) was comparable between the normal and reduced UGT1A1 expression groups (data not shown).
Eight of the nine subjects had at least one wild-type CYP2D6 allele and were therefore classified as CYP2D6 extensive metabolizers, whereas subject 7 in group 2 was homozygous for the CYP2D*4 allele and was classified as a CYP2D6 poor metabolizer. Subject 7 also had a UGT1A1*28 TA6/TA7 genotype and was classified as having reduced expression of UGT1A1. Despite carrying these mutations, the BMS-690514 plasma AUC(INF) value for subject 7 (1659 ng ⅐ h/ml) was between the values for the other subjects in the bile collection group (1535 and 1880 ng ⅐ h/ml) and was similar to values of the group 1 subjects.
The individual 3 to 8 h bile profiles from the three patients in group 2 (Fig. 6 , A-C) indicated that a direct glucuronide metabolite, M6, represented a large proportion of the biliary sample radioactivity for all three subjects. M6 accounted for the highest proportion of biliary Group 1 (without bile collection); group 2 (with bile collection). Data are presented as median (minimum, maximum), geometric mean (coefficient of variance percent), or mean Ϯ S.D.
BMS-690514
Total Radioactivity
Group 1 (n ϭ 6) 0.5 (0.5, 1.0) 173.55 (44) 
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org Downloaded from radioactivity (70%) for subject 7 compared with that for the other subjects (51-54%). Subject 7 also had a lower proportion of secondary glucuronides (M7, M8, and M9), conjugates of oxidative metabolites. Although subject 8 was identified as having normal expression of UGT1A1, this subject did not have a higher proportion of the M6 metabolite than subjects 7 and 9, who were classified as having reduced expression of UGT1A1.
Activities of BMS-690514 and Its Primary Metabolites against HER and VEGFR.
The inhibitory activities of BMS-690514 and its primary metabolites M1, M2, M3, and M6 were determined with in vitro enzymatic assays for EGFR, HER2, and VEGFR2. In addition, the potential for BMS-690514 and M2, M3, and M6 to inhibit tumor cell proliferation was assessed in an N87 cell proliferation assay (Table 5) . N87 is a human gastric tumor cell line with HER2 gene amplification. In the enzymatic assays, BMS-690514 inhibited EGFR more potently than the metabolites; metabolites M2, M3, and M6 were all approximately 4-to 5-fold less potent than the parent compound, whereas M1 was Ͼ200-fold less potent. Metabolites M2 and M6 showed HER2 inhibition similar to that of BMS-690514, whereas M3 and M1 were 6-and Ͼ27-fold less potent for this enzyme, respectively. BMS-690514 inhibited VEGFR2 Ͼ18-fold more potently than metabolites M1, M2, and M6. Metabolite M3 was approximately 10-fold more potent in inhibiting VEGFR2 than the parent compound.
In the N87 cell proliferation assay, the potencies of metabolites M2, M3, and M6 were all Ͻ10-fold that of BMS-690514, and the metabolite activities were all appreciably reduced in the cell proliferation assay compared with the enzymatic assay for HER2. Given its weak enzymatic potency, M1 was not evaluated in the cell proliferation assay.
Discussion
This study describes the disposition of [ 14 C]BMS-690514 after administration of a single oral dose to nine healthy male subjects. On the basis of the recovery of the dose and metabolic profiles, the 14 C-labeling scheme, with the label distributed uniformly on the aromatic carbons of the methoxyaniline group, was appropriate for this study. Furthermore, the use of AMS for analysis of drug-derived 14 C radioactivity in plasma facilitated the measurement of BMS-690514 equivalents in plasma for at least 96 h postdose, the period over which the parent drug was measurable with an LC-MS/MS assay. Given its lower sensitivity (estimated LOQ ϳ400 ng/ml at the specific activity used in this study), liquid scintillation counting would only have permitted measurement of plasma radioactivity through ϳ8 -12 h postdose.
BMS-690514 was rapidly absorbed into the systemic circulation with a median T max of 0.5 and 2 h for parent compound and TRA, respectively ( Table 2 ). The mean AUC(INF) ratios of BMS-690514 to TRA were Յ7.9% for both groups, indicating that systemic exposure to BMS-690514-derived radioactivity was mostly due to metabolites. Consistently, the metabolic profiles of 1 to 8 h plasma samples demonstrated the presence of several metabolites, which significantly contributed to plasma radioactivity ( Fig. 4; Table 3 ). Although the two groups had a similar AUC(INF) exposure of BMS-690514, the mean AUC(INF) of TRA for subjects in group 2 (n ϭ 3, bile collection) was generally lower than that for group 1 (n ϭ 6, no bile collection). This difference may reflect interruption of enterohepatic recirculation in the subjects who underwent bile collection. In addition, the mean half-life for TRA (Ͼ170 h) was considerably longer than that of the parent FIG. 5 . Representative biotransformation profiles of pooled 0 to 192 h urine from group 1 subjects (A), pooled 0 to 192 h feces from group 1 subjects (B), and pooledcompound (16 -18 h), suggesting that a slower elimination rate limited clearance of the metabolites that constitute total radioactivity. These data suggest that any re-absorbed drug recirculated primarily as metabolites or that the oxidative metabolites underwent enterohepatic circulation.
Human circulating metabolites included M6, an O-glucuronide of BMS-690514; M1, a hydroxylated rearrangement product; M3, an O-demethylated metabolite; and multiple secondary glucuronide conjugates. The prominent human metabolites (M1, M7, M9, and M6) were each present in the plasma of the preclinical toxicology species (rat, rabbit, and dog) (Hong et al., 2010) , and each metabolite was present in at least one of the animal species at exposures that were similar to or exceeded the human exposure. Earlier analysis suggested that the primary metabolites of BMS-690514 are not likely to be reactive (Hong et al., 2010) ; the remaining human circulating metabolites were predominantly O-glucuronide conjugates that are also unlikely to be reactive or to demonstrate pharmacological activity.
The mean total recovery of radioactivity was 85 and 100% for groups 1 and 2, respectively (Fig. 2) . Across the two groups, the majority of administered radioactivity (50 -52%) was recovered in feces with a substantial portion of BMS-690514-derived radioactivity excreted in urine (34%). For group 2 subjects, an additional 16% of administered radioactivity was recovered in the 3 to 8 h bile, indicating that biliary excretion was an important excretion pathway of drug-derived radioactivity. Based on the recovery of radioactivity in group 2 subjects in urine (34%) and bile (16%) and as known metabolites in the feces (18%), it is estimated that between 50 and 68% of the dose was absorbed from the gastrointestinal tract.
Only a small portion of the administered dose (3-4%, as determined with a validated bioanalytical assay) ( Table 1 ) was recovered as unchanged parent drug in the urine, suggesting that direct urinary excretion was not an important route for the clearance of BMS-690514. Therefore, the pharmacokinetics of BMS-690514 in renally impaired patients is expected to be similar to that of patients with normal renal function. Biliary excretion was also not a major route for the elimination of BMS-690514, as only 0.6% of the radioactive dose was recovered as parent compound in the bile (Table 4) . Approximately 17 to 20% of the dose was recovered as BMS-690514 in feces. Because large amounts of the glucuronide conjugate, M6, were excreted in bile and BMS-690514 is a substrate for P-gp (Marathe et al., 2010) , the parent drug observed in feces is probably derived from three sources: biliary excretion of M6 and parent drug, direct intestinal secretion, and unabsorbed drug. Taken together, these data suggest that BMS-690514 was highly metabolized in humans.
Studies with hepatocytes and in vivo animal absorption, distribution, metabolism, and excretion studies (Hong et al., 2010; Marathe et al., 2010) identified the metabolic pathways for BMS-690514, which included glucuronidation to M6, hydroxylation to M1, M2, and M37, O-demethylation to M3, and conjugation of oxidative metabolites (Fig. 1) . Similar metabolic pathways were identified in humans. For group 2 subjects, the metabolite M6 was the predominant drug-related component in both urine and bile but was barely detectable in the 0 to 168 h fecal samples (Table 4 ; Fig. 5 ), suggesting hydrolysis by the gut microflora before reabsorption or excretion in the feces, a conversion that is well documented (Walker, 1973) . Without bile data, the involvement of this pathway in the overall metabolism of BMS-690514 would be underappreciated. Because of the limited bile collection period, the total recovery of M6 (15.7% of the dose) (Table 4) is likely to be an underestimation of the total flux through this glucuronidation pathway. The flux through the P450-mediated pathways was estimated to be approximately 12 to 16% of the dose for M2 and M37 combined and 20 to 25% for M3. Significant amounts of M1 were not detected in the excreta samples; however, the formation of M1 was a major metabolic pathway in human liver microsomes (data not shown). Taken together, these data suggest that the metabolism of BMS-690514 occurs via multiple metabolic pathways. This balanced metabolism may mitigate the potential for significant clinical inhibitory drug-drug interactions with BMS-690514 as a victim.
Earlier in vitro studies indicated that CYP3A4 and CYP2D6 were probably involved in the oxidative metabolism of BMS-690514 and that the compound was also subject to direct glucuronidation (Marathe et al., 2010) . In the present study, there were no clinically relevant differences in the plasma pharmacokinetics of BMS-690514 between subject 7, an individual classified as a CYP2D6 poor metabolizer, and subjects 8 and 9, who were both classified as extensive CYP2D6 metabolizers. Al- N.E., M1 was not evaluated in the N87 tumor cell proliferation assay.
FIG. 6. Individual metabolite profiles of bile collected 3 to 8 h postdose from subject 7 (A), subject 8 (B), and subject 9 (C) in group 2. Subject 7 had a CYP2D6*4/*4 genotype; subjects 8 and 9 were CYP2D6*1/*1 and CYP2D6*1/*4, respectively. All three subjects has at least one UGT1A1*1 allele.
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org though subject 7 also carried a reduced expression UGT1A1 polymorphism, the biliary metabolite profile from this subject showed a larger percentage of M6, a direct glucuronide conjugate of BMS-690514, and lower percentages of glucuronides of oxidative metabolites compared with subjects 8 and 9. In total, these results suggest that in subjects who are poor CYP2D6 metabolizers, other metabolic pathways may participate in BMS-690514 elimination, resulting in similar exposures of the parent compound. Comparable systemic exposures of BMS-690514 were also observed among subjects having reduced UGT1A1 expression and those having normal UGT1A1 expression, indicating that UGT1A1 is most likely not involved in the glucuronidation of BMS-690514 to form M6. Further studies to assess the role of various P450 and UGT enzymes in the metabolism of BMS-690514 are underway. In addition, the impact of polymorphisms of drug-metabolizing enzymes and coadministration of P450 inhibitors with BMS-690514 on its exposure will be assessed in future clinical studies. Metoclopramide was administered intravenously to group 2 subjects at approximately 1 h postdose to facilitate the placement of an oral gastroduodenal tube. In addition, sincalide was given intravenously to group 2 subjects at 7 h after the [ 14 C]BMS-690514 dose to stimulate gallbladder contraction before the end of bile collection. Although metoclopramide and sincalide are prokinetic agents that stimulate gastric emptying and gastrointestinal transit (Desta et al., 2002; Bracco Diagnostics, 2004) and metoclopramide is also known to inhibit CYP2D6 in vitro (Desta et al., 2002) , the T max values of BMS-690514 and TRA in group 2 subjects (Table 2) did not appear to be affected by the use of these agents. In addition, the AUC(INF) values of BMS-690514 in groups 1 and 2 were similar, indicating a minimal effect on the pharmacokinetics of BMS-690514.
Metabolite M1 was inactive in the in vitro receptor-based assays. Although three other metabolites (M2, M3, and M6) showed some activity in the in vitro receptor-based assays, these metabolites showed minimal activity or were inactive in a N87 cell-based model (Table 5 ). The glucuronide conjugates of oxidative metabolites are also expected to be inactive. Taken together, these data suggest that the circulating metabolites are not expected to contribute to the pharmacology of the drug.
In summary, BMS-690514 was rapidly absorbed and extensively metabolized in humans after a single 200-mg oral dose, with the majority of drug-related radioactivity excreted through the bile into feces. The primary metabolic pathways included multiple oxidations and direct glucuronidation; however, because of the potential for enterohepatic recirculation, the ultimate contribution of glucuronidation to the overall clearance of the compound is not known. All human circulating metabolites were represented in rat, rabbit, and dog, the preclinical toxicology species. None of the metabolites is expected to contribute to the pharmacology of the drug.
